+34 679 490 537info@nanbiosis.com



26 Feb

Fabry disease & Smart4Fabry project

The Fabry disease (FD) is a lysosomal storage disorder (LSD) that currently lacks an effective treatment. Lysosomes are spherical vesicles, which contain hydrolytic enzymes found in nearly all animal cells. LSDs are caused by lysosomal dysfunctions, usually because of the deficiency of a single enzyme required for the metabolism of macromolecules such as lipids, glycoproteins and mucopolysaccharides. Fabry disease is a progressive, X-linked inherited disorder caused by deficiency or absence of the α-galactosidase A (GLA) activity, an enzyme involved in the glycosphingolipid metabolism. The substrates of GLA are glycosphingolipids, being the primary substrate the globotriaosylceramide (Gb3). Therefore, the failure of GLA activity leads[...]

04 Feb

NANBIOSIS Against Cancer

The World Health Organization, the International Cancer Research Center (IARC) and the International Union Against Cancer (UICC) celebrate February 4 of each year as World Cancer Day Every year, 14 million new cases of cancer are diagnosed worldwide and the disease causes 8.2 million deaths. Thanks to scientific research, great advances have been made in the fight against cancer. Through surgery, chemotherapy or radio therapy and, in the last 20 years, through immunotherapy, hormonal treatment or cell therapies, tools have been obtained to improve early diagnosis and treatments, increasing cancer survival by 20%. The only way to understand cancer and,[...]

14 Nov

Drive Pannel Diabetes - Nanbiosis
Diabetes mellitus and pancreatic islet transplant: DRIVE

Today in the World Diabetes Day it is a good moment to remember The Patient Panel of the European project DRIVE- Diabetes Reversing Implants, held in Vitoria (Alava) on June 2 where researches and doctors met with patients and families. The Panel was organized by the NanoBioCel group of CIBER BBN and NANBIOSIS Unit 10 Drug Formulation, with the purpose of letting know the DRIVE project to patients and concect patients with the project scientists and experts in pancreas and stem cell transplantation. Thus, one of the most important health objectives of the European Union was met: to promote direct[...]

19 Jul

Mechanical Characterization of soft biological tissues - Nanbiosis
Mechanical Characterization of soft biological tissues

The experimental study of the mechanical properties of biological tissues is of vital importance. Thorough research into themechanical response of biomaterials is the basis for the creation ofmodels which can accurately reproduce the mechanical behavior ofsuch materials. Adequate mechanical characterization of tissue materials is of paramount interest to the clinical simulations, diagnostic and tissue engineering fields – where the tissue structure, in contrast to classical mechanics application fields, is just simply a biological tissue. In order to obtain their material properties, classical engineering testing techniques have been applied to biologicalmaterials. To reproduce the mechanical behavior of these kinds ofmaterial, many[...]

16 Jan

U12-Nanostructured liquid characterization unit
Characterization of nanomedicines

The quick development of nanotechnology and its application in medicine have generated new alternatives for the diagnosis and treatment of diseases thanks to the novel methods of preparation, modification and characterization of nanomaterials. The knowledge about the behavior of matter at the atomic and molecular level has allowed the creation of tools and processes to observe manipulate and control biological structures on a scale between 100 and 10,000 times smaller than a mammalian cell. Nanomedicine is defined as the application of nanotechnology in view of making a medical diagnosis or treating or preventing diseases. It exploits the improved and often[...]

News about Nanbiosis

18 Sep

Scientists of Bionand, University of Malaga and CIBER identify a new drug that could mitigate the consequences of COVID infection.

Researchers from Bionand, partner of NANBIOSIS and ​​the University of Malaga toguether with Red de Terapia Celular, CIBER-BBN and CIBER-NED have taken another step in the search for new rapidly implantable therapies to stop the pandemic caused by the coronavirus disease, identifying a new drug that could prevent or mitigate the consequences of the SARS-CoV-2 infection. The team, led by UMA researchers Iván Durán and Fabiana Csukasi, will study over the next year how treatment with 4-Phenylbutyrate (4-PBA) modulates the inflammatory response that occurs in the most severe cases of COVID-19. The first results have already been published in t[...]

17 Sep

New project to alleviate the effects of Covid will be developed by JUMISC, partner of NANBIOSIS

The Jesús Usón Minimally Invasive Surgery Center (JUMISC), partner of NANBIOSIS, will develop an R&D project aimed at alleviating the effects of the health and social crisis of COVID-19, thanks to a collaboration agreement with Banco Santander. The project “Analysis of ligands for SARS-CoV-2 in lymphocyte subpopulations with application for disease staging and patient stratification“, will be developed for a year with the collaboration of researchers from from the San Pedro de Alcántara Hospital in Cáceres, the University of Extremadura, the Reina Sofía Hospital and Mount Sinai in New York. This research initiative aims to provide a reliable prediction of[...]

16 Sep

Maastricht Simulation Award to Konstantinos Mountris and Esther Pueyo

Konstantinos Mountris and Esther Pueyo, (NANBIOSIS Unit 27 High Performance Computing), have been awarded with the Maastricht Simulation Award for their participation in the CinC 2020. Researchers of BSICoS Group, from CIBER-BBN and I3A of Zaragoza University, have participated in the 47 Computing in Cardiology Conference, which took place in Rimini, Italy, during the days 13-16 of September. Alba Martín, was awarded with the Best Remote Poster Presentation for the poster entitled “Model-based characterization of atrial fibrilation episodes and its clinical association“. And the work “Next-generation in-silico Cardiac Electrophysiology through Immersed Grid Meshfree Modelling. Application to Simulation of Myocardial Infarction”[...]

15 Sep


JOINT OITBS OPEN CALL TO FIGHT COVID 19 SAFE-N-MEDTECH OITB project in which CIBER-BBN is a partner througth its ICTS NANBIOSIS, gathers expertise from 28 partners around the World focused in enabling the safe translation of nano-enabled medical technologies from Proof of Concept to markets and clinical practice. The sudden COVID-19 outbreak has meant an unforeseen challenge that requires rapid answers from the Science, Technology and Innovation Community. These is a framework where SafeNMT could deploy all its potential: first, because nanotechnology is a Key Enabling Technology that can contribute to innovative approaches to fight COVID 19 and/or other vira[...]

10 Sep

Robust Conditional Independence maps of single-voxel Magnetic Resonance Spectra to elucidate associations between brain tumours and metabolites

Scientists of CIBER-BBN, Ana Paula Candiota and Margarida Juliá managing Nanbiosis ICTS U25 NMR: Biomedical Applications I have participated in the research carried out by Liverpool John Moores University and University of Valencia to elucidate associations between brain tumours and metabolites, published by the journal Plos One. The aim of the paper is two-fold. First, to show that structure finding with the PC algorithm can be inherently unstable and requires further operational constraints in order to consistently obtain models that are faithful to the data. The authors propose a methodology to stabilise the structure finding process, minimising both false positiv[...]

18 Aug

The ATTRACT Online Conference open for registration

The on line Conference ATTRACT – Igniting the Deep Tech Revolution will take pace on 22-23 Sep 2020. The ATTRACT Online Conference website is now live! Please register before 28 August at https://attract-eu-conference.cern.b2match.io/ The ATTRACT Conference offers multiple opportunities to understand the dynamics and contribute to the emergence of a strong European deep tech ecosystem for detection and imaging technologies. The ATTRACT Project is an EC funded initiative led by a consortium of leading European research infrastructures and universities. CIBERBBN and Nanbiosis are involved in MAGRes : Multiparametric MR approaches for non-invasive glioblastoma therapy response follow-up, one of the 170 projects using sensing and imaging technologyto[...]

17 Aug

The University of Zaragoza, in the elite of the 500 best universities in the world

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, once again places the University of Zaragoza among the elite of the 500 best universities in the world. This indicator organizes up to 20,000 university centers worldwide. Among the keys that have been able to positively influence the results of the research, according to the Vice Chancellor for Prospect, Sustainability and Infrastructure of the University of Zaragoza, Francisco Serón, are the increase in public campus funding for four years as well as the quality of their Scientists. The University of Zaragoza houses[...]

17 Aug

The Autonomous University of Barcelona, in the elite of the 300 best universities in the world

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world and the first of the Spanish universities. This indicator organizes up to 20,000 university centers worldwide, based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings The Autonomous University of Barcelona houses two of NANBIOSIS Units: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Paolo Saccardo, offer an “tailored”[...]

10 Aug

The Immunomodulatory Signature of Extracellular Vesicles From Cardiosphere-Derived Cells: A Proteomic and miRNA Profiling

Researcher of CCMIJU published an article in the scientific journal FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY with the participation of NANBIOSIS Unit 14 of Cell Stem CellTherapy where culture and in vitro studies wereperformed, The researchers have shown that the regenerative potential and immunomodulatory capacity of cardiosphere-derived cells (CDCs) is mediated by paracrine mechanisms. In this process, extracellular vesicles derived from CDCs (EV-CDCs) are key mediators of their therapeutic effect. Considering the future applicability of these vesicles in human diseases, an accurate preclinical-to-clinical translation is needed, as well as an exhaustive molecular characterization of animal-derived therapeutic products. Based on that,[...]

31 Jul

A Study of Fluid Dynamics and Chemical Parameters

Researchers of NANBIOSIS -ICTS U9, Synthesis of Nanoparticles Unit, from CIBER-BBN andAragon Institute of Nanoscience (INA), have published an interesting study on the Scientific Jounal Materials of Fluid Dynamics  and  Chemical Parameters. The objective of the the work was to produce gastroresistant Eudragit (R) RS100 nanoparticles by a reproducible synthesis approach that ensured mono-disperse nanoparticles under the size of 100 nm. Batch and micromixing nanoprecipitation approaches were selected to produce the demanded nanoparticles, identifying the critical parameters affecting the synthesis process. To shed some light on the formulation of the targeted nanoparticles, the effects of particle size and homogeneity of fluid dynamics,[...]

26 Jul

Innovation Radar “Great EU-funded Innovations”

The Innovation Radar Platform is a European Commission initiative to identify high potential innovations and innovators in EU-funded research and innovation framework programmes based on their market readiness. Researchers of NANBIOSIS U8 Micro– Nano Technology Unit, led by Rosa Villa, contribute to the @InnoRadarEU with two innovations related to their research on graphene-based neuroprobes: Flexible neural probes for monitoring infraslow brain activity This innovation was developed under the Horizon 2020 project GrapheneCore2 by CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED (CIBER), FUNDACIO INSTITUT CATALA DE NANOCIENCIA I NANOTECNOLOGIA (ICN2) and AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS (CSIC) Multiplexed Neurosensor Arrays based[...]

23 Jul

II Conference on Nanotoxicity, organised by Nanomed Spain, NANBIOSIS and Materplat, Sept. 22

NANBIOSIS is organizing an on-line Conference on Nanotoxicity in collaboration with Nanomed Spain and Materplat, next September 23, to debate about the efect of nanotoxicity of nanoparticles and nanotechnologies in health. Nanotechnology, a science involved in the design, production, and use of structures and objects that have at least one of their dimensions on the scale of 100 nanometers or less, is enabling progress to be made in various areas with far-reaching repercussions. scope for society. Currently, there are several areas in which nanotechnology is under development or even in the practical application phase. However, manufactured nanoparticles can have very different properties and effects[...]

23 Jul

Workshops on Robotic Surgery with experimental models at CCMIJU

This year, CCMIJU, partner of NANBIOSIS, at Cáceres, has organised some new hands-on and customised workshops with robotic technology, expected for 2020 last term. Specifically CCMIJU is organising, in collaboration with the Enterprise ABEX-Excelencia Robótica SL, some workshops on Robotic Surgery (da Vinci Xi) using experimental models. They are addressed to health professionals from several specialties (urology, gynaecology, general surgery and thoracic surgery) interested in practising with this technology. The workshops will count on a clinical specialist from ABEX, who will explain the technical features of the robotic equipment, the associated technologies and the virtual simulator for exercises. Subsequently the health professionals,[...]

22 Jul

The Scientific Director of NANBIOSIS Unit 7, awarded with the Narcís Monturiol medal for his contribution to science and technology

The Catalan Government announced yesterday the Narcís Monturiol Medal award for scientific and technological merit to the Director of NANBIOSIS Unit 7 Nanotechnology Unit from CIBER-BBN and IBEC, Josep Samitier Martí, for his contribution to the development of the Catalan system of science and technology. The Narcís Monturiol Prize was established by the Generalitat of Catalonia in 1982, in honor of the Catalan scientist and inventor Narciso Monturiol, to award the people and entities that have made an outstanding contribution to the scientific and technological progress of Catalonia. It is awarded in the form of medals and plaques. The medals[...]

16 Jul

Unlocking the brain with novel graphene technology

Researchers of NANBIOSIS U8 Micro– Nano Technology Unit of CIBER-BBN at the Barcelona Institute of Microelectronics have participated in the recent developments of a new graphene-based detection platform that could be the gateway to unlock superior understanding of the brain by providing a measure of high brain activity resolution and in real time. This research has been developed within the framework of the EU BrainCom project. The European Union’s Horizon 2020 research project, BrainCom, is coordinated by the ICN2 Advanced Electronic Materials and Devices Group led by Professor José A. Garrido and the CIBER BBN GBIO Group and the Nanbiosis[...]

15 Jul

Biocidal releasing dressings of natural origin to treat topical wounds and avoid antibiotic resistance

Researchers of NANBIOSIS U9 Synthesis of Nanoparticles Unit, of the CIBER-BBN at the University of Zaragoza, use thymol as a natural biocide, a component present in the essential oils of thyme and oregano, thus fighting against the predictions that in 2050 there will be more deaths from infections associated with antibiotic-resistant bacteria than from cancer. Some topical wounds caused by burns, by surgical procedures, diabetic foot ulcers, fistulas, pressure ulcers, etc. they can become infected and become chronic, rendering current treatments ineffective. Currently, the devitalized tissue is removed, the area is cleaned, it is drained and depending on the microbia[...]

13 Jul

Cardiac hypertrophy research with NANBIOSIS unit 17 Confocal Microscopy Service participation

A new article has been recently published about Cardiac hypertrophy research in the Scientific Reports Jorunal by NatureResarch, counting with the expertise of NANBIOSIS unit 17 Confocal Microscopy Service form CIBER-BBN and University of Alcalá de Henares. Cardiac hypertrophy is the abnormal enlargement, or thickening, of the heart muscle, resulting from increases in cardiomyocyte size and changes in other heart muscle components, such as extracellular matrix. This article relates more especifically with the link between long term exposure to xenoestrogen Bisphenol-A and adverse cardiovascular effects and the role of necroptosis in cardiac response to BPA had not yet been explored.[...]

09 Jul

A new nanoconjugate blocks acute myeloid leukemia tumor cells without harming healthy ones

Researchers from NANBIOSIS U18 Nanotoxicology Unit at the Institut d’Investigació Biomèdica de Sant Pau (IIB Sant Pau) and NANBIOSIS U1 Protein Production Platform (PPP) at the Universitat Autònoma de Barcelona (UAB) toghether with researchers of Institut de Recerca contra la Leucèmia Josep Carreras (IJC) have demonstrated the efficacy of a new nanoconjugate, designed in house, that blocks dissemination of leukemic cells in animal models of acute myeloid leukemia. These results have been published in a high impact scientific journal in the field of oncology and hematology, Journal of Hematology and Oncology. Most of the experimental work has been performed in[...]

03 Jul

From natural by-products to cell delivery systems for regenerative medicine

Researchers from NANBIOSIS U10 Drug Formulation unit (CIBERBBN – UPV/EHU led Rosa María Hernández, have developed a biomedical device consisting of by-products from the food industry and which displays excellent properties for use in regenerative medicine. The work has been published in the Green Chemistry Jurnal, one of the most prestigious international journals in chemistry and the second most important one in the field of sustainable science. The work has also been selected for the cover page of this issue. Researchers in the UPV/EHU’s NanoBioCel and Biomat groups have developed a biomedical device consisting of by-products from the food industry and which displays excellent[...]

29 Jun

II Course on introcuction to research and laboratory techniques in biomedicine

JUMISC has organised the Course on introcuction to research and laboratory techniques in biomedicine which wil take place during the month of July, co-Directed by Francisco M. Sanchez Margallo, Deputy Scientific Director of NANBIOSIS  and Javier García Casado, Scientific Director of NANBIOSIS unit 14 Cell Therapy. Further information and programe: here Inscriptions: her[...]

25 Jun

Manuel Doblaré, researcher of NANBIOSIS U13, new Chairman of IMDEA Materials Foundation

Manuel Doblaré researcher of the Group Applied Mechanics and Bioengineering – AMB and NANBIOSIS U13 Tissue & Scaffold Characterization Unit of CIBER-BBN and I3A presides, from this month, the Board of Trustees of the Imdea Materiales Foundation. The IMDEA Materials Institute, one of the seven Madrid Institutes for Advanced Studies (IMDEA), is a public research centre founded in 2007 by Madrid’s regional government. The goal of the Institute is to do research at the forefront of Material Science and Engineering, attracting talent from all around the globe, and collaborating with companies in an effort to transfer fundamental and applied knowledge into[...]

25 Jun

NANBIOSIS scientists in Aragón, explain on TV their research againts coronavirus

The special program on the coronavirus pandemic  by “En Ruta con la Ciencia” of Aragón Televisión, analyzes different aspects of the disease with special attention to the work of Aragonese scientists. Among them, two  research groups that coordinate NANBIOSIS units 9 and 27. Starting at minute 44’45 ‘of the program, Doctor Jesús Lázaro, researcher of the BSICoS group of I3A-UZ and CIBER-BBN, led by Pablo Laguna, which coordinates NANBIOSIS U27 High Performance Computing Unit, explains his research. For almost 3 years, Jesús Lázaro had been working on a European project to develop a respiratory and heart rate monitoring system for[...]

23 Jun

Optimization of Recycled-Membrane Biofilm Reactor as a sustainable biological treatment for microcystins removal with nanbiosis expertise.

Jesús Morón-López (IMDEA), Serena Molina (Chemical Engineering Department, University of Alcalá) have recently published the results of their research about Recycled-Membrane Biofilm Reactor as a sustainable biological treatment for microcystins (MC) removal. The study addresses the lack of sustainable technologies for water treatment, while opening an alternative in sustainable solid waste management under a circular economy approach. The biofilm visualization has been performed by ICTS “NANBIOSIS”, more specifically by the Unit 17 Confocal Microscopy Service of Ciber in Bioengineering, Biomaterials & Nanomedicine (CIBER-BNN) at the Alcala University (CAI Medicine Biology) led by Juan Manuel Bellón y Gemma Pascual. In this[...]

21 Jun

The European Commission releases a video showing the European project against coronavirus led by prof Laura Lechuga

The European Commission Representation in Barcelona has published the five-minute video “The EU fights the Covid-19 from Catalonia” in which four researchers explain the projects they are working on. The researchers appearing in the video are  Laura Lechuga Scientific Director of NANBIOSIS unit 4 from CIBER-BBN and ICN2-CSIC and Group Leader of CIBER-BBN at the ICN2 Nanobiosensors and Bioanalytical Applications Group), who works on a sensor to detect the coronavirus in a faster, easier and cheaper way than with current PCRs, Núria Montserrat (IBEC), who works on micro-kidneys made from stem cells to test a drug able to block the virus, Alfonso Valencia (BSC), who explains[...]

17 Jun

Hydrogels structured with dual stimuli responsive for biomedical applications

Researchers of NANBIOSIS Unit 17 Confocal Microscopy Service have participated in the research carried out structuring hydrophobic domains in Poly(N-isopropylacrylamide-co-Methacrylic acid) hydrogels for biomedical aplplications. Hydrogels are cross-linked polymeric networks, which have the ability to hold a large amount of water in their structure. Hydrogels can be designed to respond to a specific stimulus such as temperature, pH, ionic strength, light, etc., making making them suitable for biomedical applications, as drug delivery. The most popular responsive polymeric hydrogel is made of poly(N-isopropylacrylamide) (PNIPAM). The copolymerization of NIPAM with an acrylic/methacrylic acid monomer permits the development of a hydrogel with a[...]

12 Jun

Seminar on Molecular probes and gated materials in biomedical applications by Ramón Martínez, now in youtube

Last June 8, 2020,  Ramón Martínez Máñez, Scientific Director of CIBER-BBN and NANBIOSIS U26, gave an on line seminar, hosted by Jaume Veciana and Anna Roig will from ICMAB-CSIC on Molecular probes and gated materials in biomedical applications and communication between nanoparticles. If you missed the seminar, you can see it now on YouTube: More information at the ICMAB website.[...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

04 Jun

Open call for contribution to the Special Issue by MDPI in IJMS about “In Vivo Biomarkers for Immunotherapy Efficacy in Brain Tumours”

Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25 NMR: Biomedical Applications I Unit (from CIBER-BBN and Autonomous University of Barcelona), is the Guest Editor of a special issue launched by MDPI in the International Journal of Molecular Sciences (IF 4.183). This special issue is about “In Vivo Biomarkers for Immunotherapy Efficacy in Brain Tumours” Contributions with papers or reviews to this issue, can be fowarded to the Guest Editor (AnaPaula.Candiota@uab.cat) with a tentative title and/or abstract. Final deadline for submission: 31/10/2020[...]

03 Jun

Expoquimia hosts the INDUSTRIAL DIALOGUES Webinars with Nora Ventosa

The International Meeting for Chemistry Expoquimia is hosting the INDUSTRIAL DIALOGUES Webinars, a total of 4 seminars discussing different topics related to the cores of the triennial meeting: circular economy, digitalization, and technology transference. This last topic will be covered by Nora Ventosa, Scientific Coordinator of NANBIOIS Unit 6Biomaterial Processing and Nanostructuring Unit On 4 June, Nora Ventosa, Nora Ventosa will be moderating the round table on the topic of technology transference both as a researcher of the Nanomol group, from CIBER-BBN and ICMAB-CSIC, and as part of the Expoquimia Organizing Comitée. The discussion will be focused on the topic “Creating tools to make innovation a reality. Science and[...]

02 Jun

Automatic Detection of Slow Conducting Channels during Substrate Ablation of Scar-Related Ventricular Arrhythmias

Researchers of BSICoS Group form CIBER-BBN and I3A-Unizar, coordinating NANBIOSIS Unit 27 tooghether with researchers of Physense group of UPF and Hospital Clinic have carried out the research which results have been just published by Journal of Interventional Cardiology. The researchers propose automatic analysis of EGM signals using the “Slow Conducting Channel Mapping Algorithm” that improves the accuracy of bipolar voltage measurements within the scar area, achieving a more detailed tissue characterization and being an operator-independent tool for accurate identification of SCCs. This last feature encourages the use of the algorithm together with EAM navigation systems as a reproducible approac[...]

01 Jun

New methods to detect Coronavirus: interactive webinar on the diagnosis of COVID-19

CSIC has orgnized an interactive webinar on new COVID-19 detection systems that brings together biotechnologist Luis Blanco, nanotechnologists Laura Lechuga and Pilar Marco, and physicist Javier Tamayo . Researchers from the Higher Council for Scientific Research (CSIC) will answer citizens’ questions about the diagnostic methods of the SARS-CoV-2 coronavirus, which causes Covid-19, in a webinar or interactive debate that will be broadcast on Wednesday, June 3, at 8:15 p.m., on the CSIC YouTube channel. The meeting will feature the participation of biotechnologist Luis Blanco, the physicist Javier Tamayo and the nanotechnologists Laura Lechuga, Scientific Director of NANBIOSIS unti 4 Biodeposition[...]

28 May

New fluorescent organic nanoparticles to see the invisible

A new nanomaterial for bioimaging has been developed by researchers at NANBIOSIS Unit 6 Biomaterial Processing and Nanostructuring Unit from the Nanomol group from ICMAB-CSIC and CIBER-BBN . The researchars are also members of the TECNIO technology transfer network ACCIÓ-Generalitat de Catalunya, together with the New Jersey Institute of Technology (NJIT, USA) and the University of Parma (UNIPR, Italy). The results of the study are the result of the TECNIOspring PLUS project co-financed by ACCIÓ and the European Commission. It is true that it is very difficult to understand what happens in our bodies if we are unable to visualise it. For example, we currently know that tumour cells[...]

27 May

Peptide‐Capped Mesoporous Nanoparticles: Toward a more Efficient Internalization of Alendronate.

Osteoporosis is an illness which appears when the osteoblast/osteoclast activities are unbalanced taking place bone resorption (caused by osteoclasts) in higher extension than bone formation (induced by osteoblasts). Alendronate is one of the most used drugs for osteoporosis treatment despite its scarce bioavailability. In an attempt to improve it, gated mesoporous silica nanoparticles, for the controlled release of alendronate, have been synthesized and characterized. These hybrid nanoparticles include labelled alendronate inside the porous, those porous are capped with a peptide designed to be selectively cleaved by cathepsin K enzyme (overexpressed in osteoclasts). Two CIBER-BBN units of the ICTS NANBIOSIS wer[...]

25 May

A recombinant SARS-CoV-2 vaccine

NANBIOSIS Protein Production Platform (PPP) Unit 1 (of CIBER-BBN and Autonomous University of Barcelona) is involved in a micro-patronage project for the development of a vaccine for COVID 19. NANBIOSIS Unit 1 is directly involved in the initial part of the Virus Like Particles and Proteins expression and purification project of SARS-COV-2 Most vaccines used today are based on either attenuated forms of the original pathogen, or are inactivated vaccines, in which the pathogen has undergone physical or chemical treatments to eliminate its infectivity. The project proposes to use a new vaccine strategy based on recombinant proteins in imitation of[...]

25 May

A project to develop rapid and early diagnostic tests of Covid-19 to reduce false negatives

The Journal Heraldo de Aragón has published an article highlighting the participation of Aragonese researchers in projects to fight Covid-19 Pandemic. Pilar Martín Duque, researcher from NANBIOSIS U9 Synthesis of Nanoparticles Unit, is leading a project financed by the Covid-19 Fund, launched by the Carlos III Health Institute (ISCIII). Thanks to this project, rapid and early diagnostic tests of Covid-19 are being developed to reduce false negatives. To read the article: https://www.heraldo.es/branded/la-tecnologia-y-la-innovacion-claves-vitales-para-el-desarrollo-sostenible/[...]

25 May

“We need a drastic change in the organization and management of science”

The Jorunal “Redacción Médica” has created an espace call Covid-19 Lessons to gather critical evaluations and recommendations of the most relevant personalities in the health sector, so that the National Health System and the professional and business ecosystem that surrounds it can draw conclusions and face future similar challenges with greater guarantees. Laura M. Lechuga, Scientific Director of NANBIOSIS U4, from CIBER-BBN at ICN2-CSIC, coordinates CONVAT, one of the projects selected by the European Commission to advance in the knowledge about the Coronavirus, adds her perspective to the document Covid-19 Lessons: “We need a drastic change in the organization and[...]

23 May

New therapy for triple negative breast cancer is successfully tested in preclinical animals

Researchers CIBER-BBN and NANBIOSIS Unit 26, the Príncipe Felipe Research Center (CIPF), the Universitat Politècnica de València (UPV) and the Institut de Recerca Biomèdica (IRB) of Barcelona manage to inhibit tumor growth, reduce metastasis and decrease the toxicity of the antitumor drug Navitoclax in preclinical animal models of triple negative breast cancer (TNBC). These types of TNBC tumors do not express any of the three receptors involved in most breast cancers (estrogen, progesterone, and HER2), so the most common treatments such as hormone therapy are not viable in these patients. This new study, led by Mar Orzáez, principal investigator of[...]

22 May

Scientific trends with the participation of NANBIOSIS expertise

Within the series of virtual conferences organized during the months of May, June and July by the Extremaduran office, two researchers of NANBIOSIS are invited speakers: Laura M. Lechuga Gómez, NANBIOSIS Unit 4 Biodeposition and Biodetection Unit (form CIBER-BBN and ICN2-CSIC); and María Coronada Fernández Calderón NANBIOSIS U16 Surface Characterization and Calorimetry Unit (from CIBER-BBN and University of Extremadura)who will talk about technologies at the service of health. The cycle ’90 minutes for Science, for innovation to bring society closer to the latest scientific trends, starts next Wednesday, May 27, at 5:00 p.m. It will deal with topics such as[...]

20 May

NAV-GAL, a new senolytic drug against cancer, on spanish TV

The work carried out by the team of researchers of CIBER-BBN and Politecnic University of Valencia, led by, Ramón Martínez Máñez, Scientific Director of NANBIOSIS U26 NMR: Biomedical Applications II, is highlighted by the Spanish TV. This team has developed a new drug against lung cancer that, along with other therapies, eliminates cells that have been bottled prematurely without harming healthy ones. The drug has been successfully administered in mice, now it comes the challenge of finding a way to administer it without damaging the patient’s healthy organs, and they propose inserting it into a capsule that would be released[...]

17 May

“Molecular probes and gated materials in biomedical applications and communication between nanoparticles” by Ramón Martínez

Next June 8, 2020, 12 pm, Ramón Martínez Máñez, Scientific Director of CIBER-BBN and NANBIOSIS U26, give an on line seminar, hosted by Jaume Veciana and Anna Roig will from ICMAB-CSIC. The development of optical molecular probes and probes based on gated nanoparticles has been an area of interest during the last decades. Optical probes are able to transform chemical information in the environment into a suitable optical signal, usually a change in colour of fluorescence. Moreover, gated materials have also been widely used for the development of drug delivery systems. Some examples of optical probes and gated materials for[...]

15 May

CoNVaT, the ‘Nanotrap’ for the coronavirus – highlighted by BBVA Fundation

Prof. Laura M. Lechuga, Scientific Director of NANBIOSIS Unit 4 Biodeposition and Biodetection Unit (from CIBER-BBN and ICN2-CSCIC) was awarded with the Physics, Innovation and Technology Award of the Royal Spanish Physics Society (RSEF) and the BBVA Foundation 2016. BBVA Foundation has dedicated an article to explain the  EU CoNVaT project, led by Laura Lechuga, whose objective is to obtain a diagnostic test for COVID-19 from the first day of infection, fast but highly sensitive, and which does not require a laboratory or qualified personnel. A test made with extremely sophisticated technology, and at the same time low cost, applicable to[...]

11 May

NANBIOSIS Scientists discover a promising effective alternative to reduse relapse rates in Diffuse Large B-cell Lymphoma Cells

Researchers of NANBIOSIS-ICTS Units from CIBER-BBN: U1 Protein Production Platform (PPP) at IBB-UAB, led by Antoni Villaverde and Unit 18 Nanotoxicology Unit at IBB-Hospital Sant Pau, led by Ramón Mangues, have demonstrated a potent T22-PE24-H6 antineoplastic effect, especially in blocking dissemination in a CXCR4+ DLBCL model without associated toxicity. Thereby, T22-PE24-H6 promises to become an effective alternative to treat CXCR4+ disseminated refractory or relapsed DLBCL patients. Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies. It is the most common form of non-Hodgkin lymphoma among adults, with an annual incidence of 7–8 cases per 100,000 people per year in the US and[...]

10 May

Neurocardiac Oscillation in Repolarization and Cardiac Arrhythmias

David Sampedro and Esther Pueyo, from NANBIOSIS Unit 27 High Performance Computing (CIBER-BBN, I3A-UZ) have conducted a research about Neurocardiac Oscillation in Repolarization and Cardiac Arrhythmias. Recent studies in humans and dogs have shown that ventricular repolarization exhibits a low-frequency (LF) oscillatory pattern following enhanced sympathetic activity, which has been related to arrhythmic risk. The appearance of LF oscillations in ventricular repolarization is, however, not immediate, but it may take up to some minutes. This study seeks to characterize the time course of the action potential (AP) duration (APD) oscillatory behavior in response to sympathetic provocations, unveil its underlying mechanisms[...]

08 May

Prof. Laura Lechuga is part of the experts advising the government on the COVID-19 crisis

The Fourth Vice-President of the Government and Minister for the Ecological Transition and the Demographic Challenge, Teresa Ribera, and the Minister of Science and Innovation, Pedro Duque, met with the Multidisciplinary Working Group that advises and supports the Ministry of Science and Innovation in scientific matters related to the COVID-19 and its future consequences. It also coordinates the preparation of reports and will propose the necessary modifications to improve the response to similar crises in the future. The group is formed by 16 experts in fields such as law, economy, biochemistry, bioinformatics, artificial intelligence, physics, statistics, immunology or medicine. Prof. Laura Lechuga, Scientific[...]

06 May

JUMISC will carry out PCR test for COVID-19 infections

The Institute of Health Carlos III (ISCIII), depending of the the Ministry of Science and Innovation, has validated thirty new centers for carrying out PCR tests for COVID-19 infections throughout Spain. The Minimally Invasive Surgery Center, together with the University of Extremadura (JUMISC), partner of NANBIOSIS, will carry out these PCR tests in the laboratory of the veterinary faculty of Cáceres, as it is a P2 biosafety laboratory that is already approved. They will have the capacity to perform 200 daily PCRs and will work with the samples that the the Extremadura Health Service will send them. In total, Spain[...]

05 May

A new compound removes senescent cells and reduces toxicity in cancer treatment

Scientists of NANBIOSIS unit 26 NMR: Biomedical Applications II, (of CIBER-BBN and the Universitat Politècnica de València), together with researchers from the Principe Felipe Research Center and the University of Cambridge confirm the therapeutic potential of using a new conjugated drug, Nav-Gal, in combination with chemotherapy Nav-Gal selectively removes tumourigenic senescent cells without attacking healthy cells and reduces the toxicity of platelets The accumulation of senescent cells plays a significant role in cancer pathogenesis and other diseases. However, senolytic drugs (intended to remove senescent cells) present significant toxicity, which limits their therapeutic benefits. Now, a new international study involving researchers[...]

03 May

Pilar Marco explains on TV her group’s research against Covid-19 pandemic

M.-Pilar Marco, Scientific Director of NANBIOSIS Unit 2 Custom Antibody Service (CAbS) has been interviewed on Spanish TV (RTVE) to talk about her research against the Covid-19 pandemic in the frame of the CSIC POC4CoV project, for the development of new and rapid diagnostic tools. Nb4D group of CIBER-BBN and IQAC-CSIC, led by Prof. Marco is working on the development of tests to increase the efficiency and speed of diagnosis of the methods currently on the market. According to Pilar Marco, the new strategy of the project differs basically in two fundamental aspects: on the one hand the technology, whic[...]

30 Apr

Scientists from NANBIOSIS selected by Barcelona Activa “Preacceleration” Program

Nora Ventosa and Nathaly Segovia, (Scientific Director and Coordinator of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit from CIBER-BBN and ICMAB_CSIC), have been selected as part of the NARTIC Project team for an incubation program by Barcelona Activa. NARTIC is a biotech project for the development of molecular therapy based on Quatsomes for diseases such as cancer. The NARTIC project has recently been selected for the 6th edition of the Preacceleration Program, an incubation program developed by Barcelona Activa for starting ventures with a high technological impact. The project team includes two researchers from the Molecular Nanoscience and Organic Materials (NANOMOL) group (from CIBER-BBN and ICMAB-CSIC): Nora Ventosa, as scientific advisor, and Nathaly Segovia, as[...]

28 Apr

Microencapsulated Insulin-Like Growth Factor-1 therapy improves cardiac function and reduces fibrosis in a porcine acute myocardial infarction model

Researchers of NANBIOSIS Units at JUMISC. led by Verónica Crisóstomo, Scientific Director of NANBIOSIS unit 24 of Medical Imaging, have just published an article in the Journal Scientific Report Cardiovascular diseases, especially ischemic heart disease, are the leading cause of mortality worldwide. Conventional treatments have contributed to reduce early mortality after an acute myocardial infarction, but do not recover the damaged myocardial tissue. In the last two decades stem cell therapy has been studied for that purpose. Nowadays it is known now that stem cells are able to secrete combinations of biomolecules that modulate the composition of the damaged cardiac[...]

26 Apr

A Concise Review on Nano-emulsion Formation by the Phase Inversion Composition (PIC) Method

Researchers of NANBIOSIS U12. Nanostructured liquid characterization unit from CIBER-BBN and IQAC-CSIC have recently published an interesting review entitled “A Concise Review on Nano-emulsion Formation by the Phase Inversion Composition (PIC) Method” in the JOURNAL OF SURFACTANTS AND DETERGENTS. https://doi.org/10.1002/jsde.12414 Studies of phase behavior and particle sizing were performed at the Nanostructured Liquid Characterization Unit, member of the NANBIOSIS ICTS.[...]

23 Apr

NANBIOSIS U27 researchers working in an App for the early diagnosis of covid-19 through mobile phones

Bsicos group researchers, from the I3A (Engineering Research Institute) of the University of Zaragoza and CIBER-BBN), Dr. Jesús Lázaro, Dr. Eduardo Gil, Dr. Raquel Bailón and Dr. Pablo Laguna, are working on a line of work for the search of solutions for the early diagnosis of Covid-19 cases, through the development of an App for mobile phones. For almost three years, Dr. Jesús Lázaro, under the supervision of Professor Pablo Laguna, from the resarch group Bsicos, which coordinate Nanbiosis U27 High Performance Computing , have been working on the European project WECARMON (Wearable Cardiorespiratory Monitor) for the development of an[...]

22 Apr

Wearable Armband Device for Daily Life Electrocardiogram Monitoring

Researchers Dr. Jesús Lázaro and Dr. Pablo Laguna, from Bsicos group, which coordinate Nanbiosis U27 High Performance Computing from I3A -Engineering Research Institute of the University of Zaragoza- and CIBER-BBN, in the framework of the European project WECARMON (Wearable Cardiorespiratory Monitor) are coauthors of the recently published article titeled “Wearable Armband Device for Daily Life Electrocardiogram Monitoring” in the Scientific Journal IEEE Transactions on Biomedical Engineering ( Early Access ) “Our long-term wearable armband is evaluated as heart rate monitor with 24h recordings during daily life”, explained Dr. Jesús Lázaro. A wearable armband electrocardiogram (ECG) monitor has been used for daily life monitoring. T[...]

20 Apr

Biosensors for Pandemics

Next 6 of May wii take place the On-line Conference Biosensors for Pandemics: Reliable and efficient nanotech-based diagnostics in emergency situations, will gather worldwide well known experts in biosensing technologies currently working in COVID-19 diagnostics or having very relevant technologies in the field. Prof. Laura Lechuga, Scientific Director of NANBIOSIS U4 Biodeposition and Biodetection Unit of CIBER-BBN and ICN2-CSIC, will be one of the speakers. Laura Lechuga is coordinating the European proyect CONVAT: advanced nanobiosensing platforms for point-of-care diagnostics and surveillance of coronavirus for rapid diagnosis and monitoring of COVID ー 19,  To join Deadlines: Abstract Submission (ePoster request): April 22,[...]

19 Apr

JUMISC will invest 7.3 million in the development of new surgical robots

The Jesús Usón Minimally Invasive Surgery Center (CCMIJU), partner of NANBIOSIS, has been granted the with the FID-CPI Innovative Public Procurement Program of the Ministry of Science and Innovation, as well as with the support of the Ministry of Economy, Science and Digital Agenda of the Board, for the development of the TREMIRS project “Minimally invasive robotic surgery systems” aimed at improve current techniques in laparoscopy and microsurgery TREMIRS will improve current robotic surgical systems, providing better service to the patient, better ergonomics to the surgeon and greater benefits to the surgical team, achieving an increase in the quality of[...]

17 Apr

Infrared sensitive hydrogels to control the regeneration of bone tissue.

NANBIOSIS U9 Synthesis of Nanoparticles Unit has participated in a research carried out bu researchers of CIBER-BBN group FIOBI-HULP at Hospital de la Paz, led by Nuria Vilaboa. reclently published in the scientific journal Biomaterials The researchers have used transgenic cells, which are incorporated into the scaffolding, to regulate the physiological production of bone growth factors and induce the osteoinduction process. Achievement of spatiotemporal control of growth factors production remains a main goal in tissue engineering. In the present work, we combined inducible transgene expression and near infrared (NIR)-responsive hydrogels technologies to develop a therapeutic platform for bone regeneration. A[...]

16 Apr

A new strategy to synthesize Chol-PEG “on demand”

Researchers of NANBIOSIS U3 Synthesis of Peptides Unit of CIBER-BBN at IQAC-CSIC, led by Miriam Royo, have published an article in the scientific journal ACS Omega that develops a method for the production of cholesterol conjugates to peptide ligands through polyethylene glycol (ND-PEG) not dispersed through a non-hydrolyzable bond. The developed methodology allows to generate stable, highly pure and well defined Chol-PEG compounds, linked to different lengths of PEG from 4 to 20 units of ethylene oxide through an ether bond. These Chol-PEG compounds were conjugated with different peptides, such as cyclic peptide (RGDfK), gluturation and a Tf1R peptide ligand,[...]

15 Apr

Nanbiosis among the European Research Infrastructures working for COVID-19 Pandemics

In response to the COVID-19 pandemic, several research infrastructures (RIs) NANBIOSIS among them, have set up specific services, such as rapid or fast track access, to allow researchers to obtain results as soon as possible. The Association of European-Level Research Infrastructures Facilities (ERF-AISBL), collects the relevant information about the initiatives on a dedicated website. NANBIOSIS provides rapid access for COVID-19 research. The ICTS offers preclinical stages services of biomedical product development, specifically, synthesis and preparation of biomolecules like antibodies, peptides, recombinant proteins, oligonucleotides for diagnostic therapeutic and prophylactic purposes.[...]

14 Apr

Rosa Villa, Scientific Director of NANBIOSIS U8, New CIBER-BBN group leader

Rosa Villa Sanz, the Scientific Director of NANBIOSIS U8 Micro– Nano Technology Unit was appointed group leader the CIBER during the last meeting of the Permanent Commission of CIBER-BBN, replacing Prof. Jordi Aguiló. Rosa Villa Sanz, graduated in Medicine from the University of Barcelona and has a doctorate from the Autonomous University of Barcelona in 1993 and a specialist in Nuclear Medicine (MIR-Hospital de Bellvitge-Barcelona), is a scientific researcher at the CSIC and leader of the Biomedical Applications Group of the Barcelona Institute of Microelectronics (CSIC), whose main research interests are the design and manufacture of Micro and Nano Systems[...]

13 Apr

COVIDー 19: diagnosis advantages and limitations of different techniques

Prof. Laura Lechuga, Scientific Director of NANBIOSIS U4 Biodeposition and Biodetection Unit of CIBER-BBN and ICN2-CSIC, who is coordinating the European proyect CONVAT for rapid diagnosis and monitoring of COVID ー 19, will be one of the speakers at the webinar organized next tuesday, 16 by the Young Academy of Spain, (JAE) about How Spanish science is contributing to the fight against COVID-19. The talk by Prof Lechuga is titled “COVIDー 19 diagnosis: advantages and limitations of different techniques” Global Young Academy (GYA) was created in 2010 at the initiative of young scientists and researchers from around the world who[...]

09 Apr

NANBIOSIS U2, U3 & U29 participate in the POC4CoV project to develop diagnostic technologies for SARS-COV-2

The Spanish Higher Council for Scientific Research (CSIC) will finance the project Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV), whose objective is to have effective diagnostic technologies for Covid-19. The Institute of Microelectronics of Barcelona (IMB-CNM-CSIC), the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) and the Institute of Materials Science of Aragon (ICMA) participate in it. The POC4CoV project aims to develop Point-of-Care (POC) devices for the in vitro diagnosis of SARS-COV-2 infection quickly and reliably, thanks to the use of multiplexed systems and the use of particular biomolecular probes. To do this, POC technological platforms will b[...]

07 Apr

Stem cells and COVID-19 research.

The Malaga Academy of Sciences has published an interesting review by Dr. José Becerra Ratia on Spanish biomedical research in relation to COVID-19 virus and, in particular, with two therapeutic novelties that have stem cells as protagonists, in one case the mesenchymal cells and in the other case the embryonic ones. Professor Becerra is Professor of Cellular Biology at the University of Malaga and Vice President of the Malaga Academy of Sciences, as well as Researcher in charge of the Bioengineering and Tissue Regeneration Laboratory that belongs to BIONAND, IBIMA CIBER-BBN and TerCel (unit 28 of NANBIOSIS U28 Nanoimaging Unit)[...]

06 Apr

COVID-19 research: preferent access to NANBIOSIS

Due to the current pandemic outbreak of COVID-19, caused by the SARS-CoV-2 virus, knowledge about the virus characteristics and the development of its possible diagnostic, treatment and prophylactic devices and systems are high priority in all research institutions worldwide. NANBIOSIS assigns high priority to the projects related to the SARS-CoV-2 virus offering preferential access. Some of the NANBIOSIS’s services have been suspended or postponed. However the call is open and the proposals will be processed and services required will be provided as soon as possible. For that purpose, A “COVID-19 Rapid Access” call has been established, valid through the year 2020. Urgent procedure will be applied[...]

01 Apr

Laser-driven direct synthesis of carbon nanodots and application as sensitizers for visible-light photocatalysis

Researchers of NANBIOSIS U9 Synthesis of Nanoparticles Unit, present the first successful synthesis of monodisperse carbon nanodots (CNDs) with tunable photoluminescence (PL) carried out by laser pyrolysis of two common volatile organic precursors such as toluene and pyridine. Remarkably, the initial chemical composition of the precursor determines the formation of undoped or N-doped CNDs and their corresponding absorption response in the visible range (expanded for the latter). Researchers have demonstrated the control and versatility of this synthesis method to tune the final outcome and its potential to explore a great number of potential solvent candidates. Furthermore, they have successfully exploited[...]

25 Mar

“Have we lernt the lesson?”

Heraldo de Aragón publishes today an opinion article written by Jesús Santamaría, Scientific Director of Nanbiosis U9 Synthesis of Nanoparticles Unit about the COVID19 Pandemic in the relation with the investment in R&D. The proffesor at the University of Zaragoza makes a quick review on the the main milestones reached by researchers to fight the COVID 19: “In early December some Wuhan residents start to get sick after visiting a local market, with what looked like flu symptoms. Nevertheless, Chinese health officials report to World Health Organization on New Year’s Eve that a group of patients presented a new ty[...]

24 Mar

NANBIOSIS keeps working in SAFE-N-MEDTECH!

On March 10-12 a two-day meeting between representatives of NANBIOSIS units, took place at the  Jesús Usón Minimum Invasive Surgery Center (CCMIJU), in Cáceres, to plan the work to be done in the coming months and carry out some tests within the framework of the European project Safe-N-MedTech. Several units of the ICTS NANBIOSIS will carry out some of the F/Q, in vivo and in vitro characterizations applied to the test cases of the project. NANBIOSIS is actively involved and works in close collaboration with the four Test Case Developers: Stryker, RCL, HELIA Biomonitoring and TECNAN. Additionally, NANBIOSIS is t[...]

20 Mar

Peptide functionalized nanoliposomes for biomolecule intracellular delivery, prepared using compressed CO2

The PhD Researcher Dolores Bueno researcher of NANOMOL Group and NANBIOSIS Unit 6 Biomaterial Processing and Nanostructuring Unit (from CIBER-BBN and ICMAB-SCIC) has defended her PhD thesis today, 20 March 2020, by videoconference from the ICMAB Meeting Room. No public was allowed due to the drastic measures of containment taken to tackle COVID-19. Peptide functionalized nanoliposomes for biomolecule intracellular delivery, prepared using compressed CO2  Abstract: Fabry disease is a rare disease caused by a gene mutation on the X-chromosome, which encodes α-galactosidase A (GLA) enzyme. The lack of GLA causes the accumulation of globotriaosylceramide at the lysosomes. The actual treatment is[...]

19 Mar


The Spanish Official State Bolletin of March 18, 2020 published the Royal Decree-Law establishing measures to support research on COVID-19, including the authorization of an extraordinary credit for direct grants for research projects and programs of the COVID-19.The Carlos III Heath Institute (ISCIII) calls for the presentation of expressions of interest to promote knowledge about SARS-CoV-2 and the CoVid disease19, as well as its impact on infected people. The aim of the proposals shall be to contribute to an efficient treatment of patient and / or public health rresponse. Proposals must be appropriate to the emergency situation and, therefore, allow[...]

17 Mar

Covid-19 vaccine resear will be founded with 30 million € by the Spanish goverment

Pedro Sánchez, the Spanish President has announced today the decision of the  Council of Ministers to allocate 30 million euro for the research of the SARS-CoV2 coronavirus vaccine. This budget item will go to the Higher Center for Scientific Research (CSIC), State Agency for Scientific Research and Technological Development, and the Carlos III Health Institute (ISCIII), dependent on the Ministry of Science and Innovation. Specifically, 25.2 million euro will go to the ISCIII, of this amount, 24 million will directly finance research projects and programs for the new coronavirus. The ISCIII, as a research funding agency in the health field,[...]

14 Mar

Laura Lechuga talks about CONVAT, the project for a faster and cheaper diagnose of COVID-19

Prof. Laura M. Lechuga, Scientific Director of NANBIOSIS Unit 4 Biodeposition and Biodetection Unit (from CIBER-BBN and ICN2-CSCIC) has been today interview by Cadena Ser Radio in the program “Hoy por Hoy” The interview can be listened in the following podcast, begining at 44 minute. ‘Convat’ is a nanotechnological device with biosensors capable of determining in less than half an hour the presence of coronavirus in a person. A sample saliva is deposited on a nanochip three centimeters long. If the saliva contains the virus, it will bind to antibodies located on the nanochip. A beam of light will be passed[...]

12 Mar

COVID-19 diagnose, faster and cheaper.

In order speed up research into the coronavirus, the European Commission recently announced a special call for projects to tackle the COVID-19, based on already developed technologies. Projectcs were prepared in a record time and 17 proposals have been awarded founds, 6 of them with spanish colaboration and only one coordinated by Spain CONVAT is a cooperation project between Spain, Italy and France coordinated by Prof. Laura M. Lechuga, Scientific Director of NANBIOSIS Unit 4 Biodeposition and Biodetection Unit (from CIBER-BBN and ICN2-CSCIC) and also participated by the group of Prof. Jordi Serra Cobo from the University of Barcelona, having extensive experienc[...]

01 Mar

New COVER in Chemistry. A European Journal: an active organic radical stable agains racemization!

The journal Chemistry. A European Journal features in its COVER the recently published article “An enantiopure propeller‐like trityl‐brominated radical: Bringing together a high racemization barrier and an efficient circularly polarized luminescent magnetic emitter” authored by rearserchers of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit, led by Jaume Veciana (CIBER-BBN, ICMAB-CSIC) Nowadays, it is necessary to know the increasingly specific requirements of electronic devices in order ot be able to find new multifunctional materials that allow obtaining more efficient devices. This article represents a step forward in the field of organic free radicals. Organic free radicals act as polarized light emitters synthesizing and[...]

27 Feb

Rare diseases Day February 29: combating Fabry Disease

29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February. NanoMed Spain Platform and the Hospital of Sant Joan de Déu have organized the NanoRareDiseaseDay to present the latest innovations in the field of Nanomedicine for the treatment and diagnosis of rare diseases (diseases affecting less than 5 people per 10,000 inhabitants). Nora Ventosa, Scientific Director of NANBIOSIS U6 Biomaterial Processing[...]

25 Feb

Course on Coloretal Endoscopy for Surgeons

JUMISC and the Spanish Association of Coloproctocology has organised the ICourse on Coloretal Endoscopy for Surgeons which wil take place at JUMISC on March, 9 -10, co-Directed by  Fernando de la Portilla de Juan (President of Spanish Association of Coloproctology) and Francisco M. Sanchez Margallo (Deputy Scientific Director of NANBIOSIS)   The course includes colonoscopy practices in pig and canine models. For further information and inscriptions: her[...]

24 Feb

#RareDiseaseDay: Fabry lysosomal disease

Rare Disease Day is annually held on the last day of February in more than 100 countries with the main objective of raising awareness about rare diseases and their impact on the life of patients to the general public and in particular to policy makers, public authorities, industry representatives, researchers and professionals. Rare diseases are those that affect less than 1 in 2000 people. There are more than 300 million people living with one or more than more than 6000 rare diseases worldwide identified. Among the events organized we wont to mention the Nano Rare Diseases Day held in Barcelona[...]

23 Feb

Preliminary Market Consultation (CPM): technology development in the field of organ preservation.

The Center for Industrial Technological Development (CDTI) has selected the proposal presented by JUMISC, partner of NANBIOSIS, on the technological challenge of an alternative cold preservation system in a preliminary market consultation.On February 4, the Technical Conference of the Preliminary Market Consultation of the Organ Preservation Challenge was held.The objective of the Preliminary Market Consultation was to obtain information from the market operators in the Organ Preservation technologies in order to adequately define the future potential for pre-commercial Public procurement and adequately inform the economic operators of the requirements that will be required in the Potential future tender for pre-commercia[...]

17 Feb

Organ-on-chip monitoring. Breakthrough technological approximations

Organ-on-chip (OOC) is the term used to define a microfluidic 3D culture model that contains continuously perfused chambers inhabited by living cells. OOC are considered as very promising tools for investigating many aspects of human physiology and pathophysiology as well as drug testing platforms with future progressions to be used for precision medicine. As the complexity of OOC systems increases, the necessity to integrate relevant assessment methods to provide information about cell physiology, secreted metabolites as well as pharmacodynamics drug responses also increases. Dr. Rosa Villa, who leads NANBIOSIS U8 Nano Technology Unit and the Biomedical Applications Group of t[...]

14 Feb

Challenges in precision medicine

Transfiere, the European Forum for Science, Technology and Innovation,  the bigest professional and multisectoral forum for the transfer of knowledge and technology held in Spain, took place last February 12 and 13 in Malaga in its 9th edition. Among the events held at Transfiere, there has been a round table organized by all health-related platforms under the title: Challenges in precision medicine on the 12th at 6pm. Maria Luisa García Martín, Scientific Director of NANBIOSIS U28 of Nanoimaging Unit and head of Nano-Imagen  facilities at BIONAND, was invited by the Nanomedicine platform, NanomedSpain as a speaker at the aforementioned round[...]

13 Feb

Mechanism and Consequences of the Impaired Hif-1α Response to Hypoxia in Human Proximal Tubular HK-2 Cells Exposed to High Glucose

NANBIOSIS has been informed about a recent publication in the pretigious scientific magzine SCIENTIFIC REPORTS (Q1) of Nature Research group, mentioning NANBIOSIS Unit 17 in the Methods section: Immunofluorescence analysis: Detection was performed by using a Leica SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany), through the Confocal Microscopy Service of the ICTS ‘NANBIOSIS’ Unit 17 of the Biomedical Research Networking Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) at the University of Alcalá, Madrid, Spain. HIF-1α-dependent immunofluorescence intensity was quantified after digital capture using image-J software. The Leica TCS-SP5 confocal microscope with especial features allows studying interactions between cells/tissues and materials.[...]

12 Feb

VII Course of Microscopic and Piezoelectric Techniques in Dentistry: Endodontics, Implantology and Prosthetics

CCMIJU has organised the VII Course of Microscopic and Piezoelectric Techniques in Dentistry: Endodontics, Implantology and Prosthetics, which wil take place at JUMISC from March 3 till June 27 2020 under the Direction of Alberto Anta Escudero. (Profesor of the UPV-EHU), Gorka Santamaría Arrieta (Professor of the UPV-EHU), Jon Eskurza Pérez (Endodontics Specialist. Private Clinic) and Francisco Miguel Sánchez Margallo (Deputy Scientific Director of NANBIOSIS) The general objective of the course is the knowledge of the enodontology magnification, necessary materials and instruments and related ergonomic aspects. Training in magnification in dentistry Frurther information: Programm and inscriptions[...]

11 Feb


In order to achieve full and equitable access and participation in science for women and girls, and also to achieve gender equality and the empowerment of women and girls, the United Nations General Assembly decided to proclaim in 2016 (resolution A / RES / 70/212) February 11 as the International Day of Women and Girls in Science. We want to take this day to congratulate all the women who lead research and innovation and contribute to the breakdown of the barriers that still exist, especially to the scientists from NANBIOSIS ICTS. Happy International Day of Women and Girls in Science![...]

10 Feb

A new smart drug that finds and kills metastasis cells could be applied in 23 types of cancer

Researchers of two CIBER-BBN Units of the ICTS NANBIOSIS  U18 Nanotoxicology Unit at Hospital Sant Pau. and U1, Protein Production Platform (PPP), at the  Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB–UAB), led by Prof Ramón Mangues, have developed a new drug that selectively removes metastatic stem cells, inducing a powerful metastasis prevention effect. Besides the participation of the “NANBIOSIS” ICTS Units U1 Protein Production Platform where Protein production was partially performed and U18 Nantoxicology Unit where Biodistribution studies were performed, all in vivo experiments were performed by the Unit 20 In Vivo Experimental Platform of CIBER[...]

07 Feb

Ethylcellulose nanoparticles as new “in vitro” tool for cell transfection

Researchers of NANBIOSIS U12 Nanostructured liquid characterization unit and U29 Oligonucleotide Synthesis Platform (OSP) of CIBER-BBN at IQAC-CSIC have obtained successfully ethylcellulose nanoparticles with positive zeta potential formed from nano-emulsion complexation with an antisense oligonucleotide which result very promising complexes for “in vitro” cell transfection. A new non-viral gene delivery vector has been developed, based on ethylcellulose, an easily available and low cost carbohydrate polymer, “generally recognized as safe” by the FDA. Although ethylcellulose is nonionic, positively charged nanoparticle dispersions have been obtained using nano-emulsion templates in cationic:non-ionic surfactant-based systems. The nanoparticles have been successfully complexed with negatively charged phosphorothioate antisens[...]

04 Feb

NANBIOSIS research to fight cancer

Twenty years ago, the 4 February was declared World Cancer Day with the global challenge of cancer would not be forgotten. Since then, huge progress has been made to understand, prevent, diagnose, and treat cancer. NANBIOSIS as an ICTS (Singular Scientific and Technical infrastructures) for biomedical research plays a very important role in the fight against cancer. Some examples of the work carried out during the last year, are bellow: Unit 20 of NANBIOSIS  at VHIR, works in several proyects reletaed to cancer as  H2020-NoCanTher: magnetic nanoparticles against pancreatic cancer through the use of hyperthermia combined with conventional treatment. H2020-Target-4-Cancer: nanotherapy based on polymeric micelles directed against[...]

30 Jan

EUROAGE: to improve people’s quality of life and increase healthy life expectancy

The Center for Minimally Invasive Surgery (JUMISC), partner of NANBIOSIS, as the main beneficiary of the Spain-Portugal EUROAGE cross-border cooperation project that promotes active aging in the region, has presented its results and its impact on society, within the Spanish-speaking meeting ‘ Forum of Iberian Stories. 30 years of the INTERREG Spain-Portugal Cross-Border Cooperation Program (POCTEP) ’. Specifically, the event has been organized by the agencies EFE and LUSA, and took place this past Wednesday at the headquarters of the Spanish agency in Madrid, with the support of the Directorate General for Regional Policy (DGRegio) of the European Commission. Its[...]

28 Jan

New book by NANBIOSIS U14: Basic research procedures in the cell therapy laboratory

Researchers of NANIOSIS Unit 14 at JUMISC have published a new book titled Basic research procedures in the cell therapy laboratory, in which some basic techniques and general principles for adult stem cell research are explained. Stem cells are cells capable of differentiating into a wide variety of cell types and can be isolated from different tissues such as. They have regenerative and anti-inflammatory properties thanks to the secretion of paracrine factors. Currently, these cells are being widely used in clinical trials for the treatment of different diseases such as Crohn disease, multiple sclerosis, diabetes, rheumatoid arthritis or myocardial infarction.[...]

28 Jan


Jose Luis Pedraz, Jesus Ciriza and Angela Losada of NANBIOSIS U10 Drug Formulation – NanoBioCel Group of CIBER-BBN and University of the Basque Country were in Leuven, Belgium attending the European Project POSITION-II Workshop #5, which was held between January 21 and 23. The workshop was held at the facilities of iMEC, one of the partners of the project and world leader in R&D in nanoelectronics and digital technology. The project lasts three years and after 18 months, in this workshop, the researchares of NANBIOSIS U10 Drug Formulation, have microencasulated and characterized the heart cells with the aim of checking[...]

27 Jan

Researchers from NANBIOSIS Unit 8 opt for the Cutting-Edge Science Award: How to measure brain’s hidden activity.

La Vanguardia and the Fundació Catalunya La Pedrera have jointly promoted for the tenth consecutive year the Cutting-Edge Science Award “La Vanguardia de la Ciencia”, with the objective of givin visibility to the research of excellence carried out in Spain. The prize will correspond to the proposal candidate most voted by the public. One of the 8 selected candidates is the research led by Anton Guimerà-Brunet (NANBIOSIS Unit 8 -Institut de Microelectrònica de Barcelona-CNM-CSIC / CIBER-BBN) and Jose Garrido (Institut Català de Nanociències i Nanotecnologia / Icrea), for developing graphene implants capable of measuring the hidden activity of the brain[...]

26 Jan

Support for companies: Nanotechnological Bonds

From the NFP research group of CIBER-BBN and INA, led by Jesus Santamaria, that coordinates NANBIOSIS U9 Synthesis of Nanoparticles Unit, and through the SAMCA Nanotechnology Chair, the call for grants has been launched: Nanotechnological Bonds For more information: http://capsulasdenanotecnologia.es/bonos-nanotec/[...]

24 Jan

PICCOLO Project 7th Face-to-Face Meeting at JUMISC (NANBIOSIS)

The Piccolo consortium members met at JUMISC (Cácere) last on 21st-22nd January to hold the 7th face-to-face meeting. Project partners had the chance to visit Nanbiosis U21 Experimental operating rooms led by Francisco M. Sánchez Margallo and participate in a training session with the prototype demo. A murine specimen was analysed ex-vivo with the probe and the clinicians had the opportunity to evaluate the features present in a neoplastic polyp. The meeting agenda included a general overview of the project, the status update of OCT (Optical Coherence Tomography), MPT (Multiphoton Tomography) and fluorescence technologies, deep learning algorithms preliminary results, t[...]

23 Jan


JUMISC has organised the II Course for the performance of functions A, B and C in rodents, lagomorphes, carnivores, pigs and small rumiants  which wil take place at JUMISC from 3 February to 20 March co-Directed by D. LUIS DÁVILA GÓMEZ, Scientific Director of NANBIOSIS U22. Animal housing and  DR. FRANCISCO MIGUEL SÁNCHEZ MARGALLO (Deputy Scientific Director of NANBIOSIS) The total duration of the course is 100 hours (58 theory and 42 practice) This course has as specific objectives to provide information and expand existing knowledge in the following aspects: -Specific legislation regarding animal experimentation . -Ethical considerations and the principles of replacement, reduction and refinement. -Biology, housing, handling and care of experimental animals. -Occupational health and safety. -Recognition of the stat[...]

20 Jan

A new fluorescent probe for NO

Nitric oxide is a component of the pollutant nitrogen oxides (NOx) responsible of different environmental negative effects. However, due to its physiological effects, NO has been used in different therapeutic applications. Thus, the inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that finds its best applications in pediatrics, by transiently improving oxygenation in respiratory failure and persistent pulmonary hypertension. The initial recommended concentration of iNO in these treatments is 20 ppm. Higher concentrations do not increase its effectiveness and are associated with a higher incidence of methemoglobinemia and formation of nitrogen dioxide. In consequence the control of iNO concentration is[...]

17 Jan

Tumor Immunology and Cancer Immunotherapy Course

The IV course on Tumor Immunology and Cancer Immunotherapy will start on 6th Feb, 2020. On April 2 at 7:00 pm Iñaki Ochoa will teach about “Basic research in cancer immunotherapy. Use of microfluidics in the study of cancer immunotherapy“. Ignacio Ochoa is a Professor of the Department of Human Anatomy and Histology of the University of Zaragoza and researcher of the AMB – Applied Mechanics and Bioengineering group and NANBIOSIS U13 Tissue & Scaffold Characterization Unit from CIBER-BBN and I3A-Zaragoza University Classes will be held on Thursday, from 4:00 p.m. to 8:00 p.m., in the CIBA Lorente de Nó[...]

16 Jan

New nanocarrier for bio-imaging and drug-delivery applications

Researchers of CIBER-BBN and NANBIOSIS-ICTS (U6 Biomaterial Processing and Nanostructuring Unit at ICMAB-CSIC and U18 Nanotoxicology Unit at  Hospital de la Santa Creu i Sant Pau have developed a new nanocarrier for bio-imaging and drug-delivery applications The new nanovesicle formulation is based on the quatsome architecture – which stands out due to the high colloidal stability and homogeneity in size – and has now been shown to be suitable for in vivo dosing. Quatsomes are new non-liposomal lipid-based nanovesicles that have been developed by Nanomol group in recent years, and have been shown to be highly homogeneous and stable in[...]

15 Jan


CCMIJU has organised the II Urological Laparoscopy Course: Suture Management and Intracorporeal Knotting which wil take place at JUMISC from 3 to 5 February under the Direction of Álvaro Serrano Pascual (Urology Service Specialist at the San Carlos Clinical Hospital, Madrid) and Francisco Miguel Sánchez Margallo (Deputy Scientific Director of NANBIOSIS) It is a basic course of Laparoscopic Urology where the techniques of Laparoscopic Radical and Partial Nephrectomy will be carried out. The objective of this course is for specialists in Urology to improve their skills in suture management and intracorporeal knotting. Programm and inscriptions her[...]

11 Jan

A step forward in the field of organic free radicals acting as chiral emitters

Researchers of NANBIOSIS U6. Biomaterial Processing and Nanostructuring Unit have just published the article titled “An enantiopure propeller ‐ like trityl ‐ brominated radical: Bringing together a high racemization barrier and an efficient circularly polarized luminescent magnetic emitter” in the scientific magazine Chemistry A European Journal. The urgent need to cope with the more and more specific requirements in electronic devices is nowadays behind the search for new multifunctional materials. In this work, a step forward has been done in the field of organic free radicals acting as chiral emitters. The recently developed brominated trityl derivative, namely TTBrM radical, shows[...]

30 Dec

A step forward for the design of multifunctional protein nanomaterials for cancer therapies

Researchers of NANBIOSIS Unit 1 and NANBIOSIS Unit 18, led by Prof Antoni Villaverde have published the article at the prestigious scintific magazine titled Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4+ colorectal cancer The researchers have shown that the combination of cell-penetrating and tumor cell-targeting peptides dramatically enhances precise tumor accumulation of protein-only nanoparticles intended for selective drug delivery, in mouse models of human colorectal cancer. This fact is a step forward for the rational design of multifunctional protein nanomaterials for improved cancer therapies. Protein production has been partially performed by the  ICTS NANBIOSIS U1, Protein Production Platform[...]

28 Dec

Pilar Marco honored by the Spanish National Research Council (CSIC)

Maria Pilar Marco Colás has been honored by the Spanish National Research Council (CSIC) in appreciation for having complited 25 years of work at the CSIC, an intense period of 25 years at the service of Science, 11 of them as Scientific Director of Custom Antibody Service (CAbS), unit 2 of NANBIOSIS since its inclusion in the national ICTS map.[...]

27 Dec

Why the poor biodistribution so far reached by tumor-targeted medicines?

Cell-selective targeting is expected to enhance effectiveness and minimize side effects of cytotoxic agents. Functionalization of drugs or drug nanoconjugates with specific cell ligands allows receptor-mediated selective cell delivery. However, it is unclear whether the incorporation of an efficient ligand into a drug vehicle is sufficient to ensure proper biodistribution upon systemic administration, and also at which extent biophysical properties of the vehicle may contribute to the accumulation in target tissues during active targeting. To approach this issue, structural robustness of self-assembling, protein-only nanoparticles targeted to the tumoral marker CXCR4 is compromised by reducing the number of histidine residues (from[...]

23 Dec

Artificial inclusion bodies for controlled drug release

Researchers from NANBIOSIS-CIBER-BBN have developed a new type of protein biomaterial that allows a continuous release over time of therapeutic proteins when administered subcutaneously in laboratory animals. These results are the result of the stable scientific collaboration between the researchers of NANBIOSIS Units 1 Protein Production Platform (PPP)and 18 Nanotoxicology Unit, led by Toni Villaverde and Ramón Mangues at the Institute of Biotechnology and Biomedicine of the Autonomous University of Barcelona (IBB-UAB) and the Institut About the Hospital de Sant Pau and has had the participation of the Institute of Biological and Technological Research of the National University of Córdoba-CONICET,[...]

17 Dec

A new method simple and efficient for the preparation of Oligonucleotide-protein conjugates

Oligonucleotide-protein conjugates have important applications in biomedicine. Four units of NANBIOSIS have collaborated to come across with more simple and efficient methods for the preparation of these conjugates. In the publication of the research results, a new method is described in which a bifunctional linker is attached to thiol-oligonucleotide to generate a reactive intermediate that is used to link to the protein. Having similar conjugation efficacy compared with the classical method in which the bifunctional linker is attached first to the protein, this new approach produces significantly more active conjugates with higher batch to batch reproducibility. In a second approach,[...]